

# CITATION REPORT

List of articles citing

Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial

DOI: [10.1007/s40273-013-0112-z](https://doi.org/10.1007/s40273-013-0112-z)

Pharmacoeconomics, 2014, 32, 87-99.

**Source:** <https://exaly.com/paper-pdf/58791561/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Addition of cotrimoxazole cost effective in IPF treatment. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2014</b> , 694, 3-3	0.1	
17	Pharmacological management of IPF. <i>Respirology</i> , <b>2016</b> , 21, 615-25	3.6	22
16	Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1865-75	1.9	1
15	A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 479-491	4.4	21
14	Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review. <i>Lung</i> , <b>2017</b> , 195, 1-8	2.9	15
13	The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 779-807	4.4	38
12	Use of animal models in IPF research. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2018</b> , 51, 73-78	3.5	41
11	Idiopathic pulmonary fibrosis: pathogenesis and management. <i>Respiratory Research</i> , <b>2018</b> , 19, 32	7.3	174
10	The effects of phycocyanin on bleomycin-induced pulmonary fibrosis and the intestinal microbiota in C57BL/6 mice. <i>Applied Microbiology and Biotechnology</i> , <b>2019</b> , 103, 8559-8569	5.7	10
9	Acute Exacerbation of Interstitial Lung Disease in Adult Patients With Idiopathic Inflammatory Myopathies: A Retrospective Case-Control Study. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 12	4.9	5
8	Can the Consideration of Societal Costs Change the Recommendation of Economic Evaluations in the Field of Rare Diseases? An Empirical Analysis. <i>Value in Health</i> , <b>2021</b> , 24, 431-442	3.3	4
7	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. <i>Efficacy and Mechanism Evaluation</i> , <b>2021</b> , 8, 1-110	1.7	
6	The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. <i>Respiratory Research</i> , <b>2021</b> , 22, 243	7.3	1
5	Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary Fibrosis: The EME-TIPAC Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 2282-2291	27.4	13
4	Data_Sheet_1.xlsx. <b>2020</b> ,		
3	Data_Sheet_2.docx. <b>2020</b> ,		
2	Table_1.docx. <b>2020</b> ,		

1 Table\_2.docx. 2020,